fda decision about compound tirzepatide BANS Compounded Tirzepatide! Now What? Tirzepatide, FDA, and Compounding: Understanding

Patch testing on a small area first can help assess tolerance

More frequent injections at lower doses do not increase efficacy and may increase side effects

Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype

The human body has the ability to adapt to exercise stressors, allowing for a greater tolerance to a subsequent similar workload, and relies on various ROS-mediated signaling pathways to do so

Accumulation of long-chain acyl-CoAs and other FA metabolites impairs insulin signaling and leads to the development of IR, a crucial pathophysiological factor for carbohydrate metabolism disorders consistent with the development of NAFLD (49)

There's always something you don't know